Pfizer’s Lipitor Patent Claims Rejected by PTO In Initial Reexamination
Executive Summary
Pfizer may lose patent protection for its blockbuster cholesterol drug Lipitor (atorvastatin) if the U.S. Patent and Trademark Office stands by an initial decision to reject the claims in the basic patent on the drug
You may also be interested in...
PTO turns down Pfizer request to reissue Lipitor patent
The Patent and Trademark Office sent a "nonfinal rejection" notice to Pfizer in response to its request for the agency to reissue a key Lipitor (atorvastatin) patent. The PTO noted that Ranbaxy had protested reissuance of the patent, contending that the patent claims were anticipated by prior art or were obvious. The agency agreed that some of the claims were anticipated or obvious but found that others were not. The U.S. Court of Appeals for the Federal Circuit ruled last year that a patent covering a Lipitor enantiomer was invalid due to technical defects in the patent. In January, Pfizer asked the PTO for permission to resubmit the patent to correct these defects. "It's common for the patent office to initially reject requests of this sort," a Pfizer spokesperson said. "We believe we have a strong argument" to address the concerns raised by PTO...
Pfizer’s U.S. Overhaul Is Paying Off, But Work Is Not Done – CEO Kindler
Pfizer's "fast-to-market" execution of Lyrica for fibromyalgia is evidence the company is already seeing the benefits of its new U.S. business structure, according to CEO Jeffrey Kindler
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.